This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Flu Vaccine (Mymetics)

Mymetics Corporation

Drug Names(s): Flu Vaccine (Mymetics)

Description: The intranasal influenza vaccine consists of the reconstituted membrane of influenza virus, also containing a lipopeptide adjuvant. In mice, intranasal application of virosomes without adjuvant does not induce immunity to influenza; however, incorporation of the lipopeptide in the virosomes produces a candidate vaccine that does induce cellular immunity, as well as serum and mucosal antibodies to the virus.

Deal Structure: In March 2009, Mymetics acquired 100% of Bestewil Holding B.V., parent company of Virosome Biologicals B.V., from Norwood Immunology Limited. The acquisition brought two collaborations, an Influenza vaccine in a Phase II Human Clinical trial in collaboration with the Solvay Group, and in collaboration with MedImmune, a Respiratory Syncytial Virus (RSV) vaccine under pre-clinical testing used to treat a major cause of respiratory illness in young children, as well as Bestewil's Herpes Simplex Virus development.

In October 2011, Mymetics terminated its license agreement with Abbott (formerly Solvay Pharmaceuticals) and reacquired the intra-nasal flu vaccine product including all the clinical trial data.


Flu Vaccine (Mymetics) News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug